Tentarix Biotherapeutics develops multifunctional biologics, known as Tentacles, that utilize synthetic biology to create conditionally-active, multi-specific binding molecules targeting specific cell surface receptors. This approach enhances treatment efficacy for cancer and autoimmune diseases while minimizing side effects by leveraging combinatorial avidity for precise cellular targeting.
Funding
$93M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AVFounders
Product
Problem
Traditional multi-specific biologics development faces challenges related to developability, complex biology, and achieving the desired pharmacological effects, limiting their potential for targeted therapies. Existing approaches often struggle with off-target effects and suboptimal efficacy in treating diseases like cancer and autoimmune disorders.
Solution
Tentarix Biotherapeutics develops multifunctional biologics, termed Tentacles, designed to address these limitations. Tentacles leverage synthetic biology to create conditionally-active, multi-specific binding molecules that target specific cell surface receptors. By binding signaling receptors and other cell markers, Tentarix's approach utilizes combinatorial avidity for precise cellular targeting, enhancing treatment efficacy while minimizing off-target effects. This strategy aims to deliver more precise therapies with improved outcomes for patients.
Target Audience
The primary target audience includes patients with cancer and autoimmune diseases, as well as pharmaceutical companies seeking innovative approaches to develop targeted therapies.
Features
- Multifunctional biologics designed for conditional activity and multi-specific binding.
- Utilizes synthetic biology to target specific cell surface receptors.
- Employs combinatorial avidity for precise targeting of cells.
- Focuses on analyzing the functionally relevant cell surface proteome to design Tentacles.